NEW YORK, July 29, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Bioabsorbable Stents Industry
http://www.reportlinker.com/p01171460/Global-Bioabsorbable-Stents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment
This report analyzes the worldwide markets for Bioabsorbable Stents in Thousand Units.
The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2018.
The report profiles 16 companies including many key and niche players such as Abbott Laboratories, Amaranth Medical, Inc., Arterial Remodeling Technologies SA, BIOTRONIK SE & Co. KG, Elixir Medical Corporation, Kyoto Medical Planning Co., Ltd., and REVA Medical, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-2Product Definitions and Scope of Study I-3II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Evolution of Coronory Stents II-1
Current Global Coronory Stent Scenario - A Few Key Facts II-2
Bioabsorbable Stents Poised to Replace Drug-Eluting Stents in
Future II-2
Market Overview II-3
Current & Future Analysis II-3
Growth Drivers II-4
Restenosis - the Real Growth Driver II-4
Aging Population Propels Coronary Stents Market II-4
Limitations and Challenges Ahead II-4
Technological Challenges II-5
Safety- Efficacy Factor II-5
Regulatory Challenges II-5
Price Factor II-5
Threats to Coronary Stents - Alternative Therapies/Devices II-5
Cell Transplantation - A Threat to Coronary Stents II-6
Regulations for Conducting Clinical Trials Bioabsorbable
Stents in Select Regions II-6
The United States II-6
Europe II-6
Australia II-7
Competitive Scenario II-7
Focus on Select Bioabsorbable Stents II-7
Absorb® (Abbott Laboratories, US) II-7
ART Bioabsorbable Stent (Arterial Remodeling Technologies,
France) II-8
DREAMS (BIOTRONIK, Germany) II-8
DESolve™ Coronary Scaffold (Elixir Medical, US) II-8
IGAKI-TAMAI® (Kyoto Medical Planning, Japan) II-8
ReZolve® (REVA Medical Inc., US) II-9
2. PRODUCT OVERVIEW II-10Coronary Artery Disease-A Perspective II-10Treatment Options for Coronary Artery Disease II-10Percutaneous Coronary Intervention (PCI) II-10Coronary Stenting II-10Types of Coronary Stents II-11Bare Metal Stents (BMS) II-11Drug Eluting Stents (DES) II-11Bioabsorbable Stents II-12Design and Composition of Bioabsorbable stents II-12Different Types of Bioabsorbable Stents II-12Metallic Bioabsorbable Stents II-12Polymer Bioabsorbable Stents II-13Degradation Period of Select Bioabsorbable Materials II-13Advantages of Bioabsorbable stents II-13Challenges II-14Other Treatment Options for Coronary Heart Disease II-15Coronary Artery Bypass Grafting (CABG) II-15Minimally Invasive Direct Coronary Artery Bypass (MIDCAB) II-15TransMyocardial Laser Revascularization (TMR) II-15Peripheral Arterial Disease: Understanding the Stealthy Peril II-15Treatment for PAD II-16Lifestyle Changes II-16Medication II-16Surgery II-17Stenting- A Treatment Option for PAD II-17Definition of Key Endpoints Used for Assessing Efficiency ofStents II-18MACE (Major Adverse Cardiac Events) II-18Restenosis II-18Stent Thrombosis II-18Target Lesion Revascularization (TLR) II-19
3. PRODUCT LAUNCH/INTRODUCTION II-20
Abbott Laboratories Launches Absorb™ BVS in Europe and Other
Select Geographies II-20
4. RECENT INDUSTRY ACTIVITY II-21Abbott Laboratories Initiates ABSORB III Clinical Trial in the US II-21ART Conducts First-in-Human Implant of ART Bioabsorbable Stent II-21Kyoto Medical Planning Releases Data to Demonstrate Efficacyof IGAKI-TAMAI® Stent II-21REVA Medical Receives Clearance to Conduct Clinical Trials forReZolve® in Brazil and Germany II-22Xenogenics Acquires Ideal™ BioStent Assets from Investment Funds II-22ART Discloses Data for ART Bioabsorbable Stent Platform II-23
5. FOCUS ON SELECT GLOBAL PLAYERS II-24
Abbott Laboratories (US) II-24
Amaranth Medical, Inc. (US) II-24
Arterial Remodeling Technologies SA (France) II-25
BIOTRONIK SE & Co. KG (Germany) II-25
Elixir Medical Corporation (US) II-25
Kyoto Medical Planning Co., Ltd. (Japan) II-26
REVA Medical, Inc. (US) II-26
6. GLOBAL MARKET PERSPECTIVE II-27Table 1: World Current and Future Analysis for BioabsorbableStents by Geographic Region - US, Europe, Asia-Pacific, andRest of World Markets Independently Analyzed with Annual Salesin '000 Units for Years 2013 through 2018 (includescorresponding Graph/Chart) II-27
Table 2: World 6-Year Perspective for Bioabsorbable Stents by
Geographic Region - Percentage Breakdown of Volume Sales for
US, Europe, Asia-Pacific, and Rest of World Markets for Years
2013 and 2018 (includes corresponding Graph/Chart) II-28
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Market Overview III-1
Growth III-1
Coronary Artery Disease - A US Perspective III-1
Baby Boomers Boost Coronary Stent Market III-1
Challenges Ahead III-2
Current and Future Analysis III-2
Products in the Pipeline III-2
Competitive Scenario III-2
Strategic Corporate Developments III-2
Key Players III-3
B.Market Analytics III-5
Table 3: The US Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-5
2. EUROPE III-6A.Market Analysis III-6Overview III-6Growth Drivers III-6Cardiovascular Disease in Europe - A Perspective III-6Highly Diverse Europe III-6Product Launch III-7Strategic Corporate Developments III-7Key Players III-9B.Market Analytics III-10Table 4: European Current and Future Analysis forBioabsorbable Stents with Annual Sales in '000 Units forYears 2013 through 2018 (includes corresponding Graph/Chart) III-10
3. ASIA-PACIFIC III-11
A.Market Analysis III-11
Overview III-11
A Few Key Facts III-11
Asia-Pacific - A Price Sensitive Market III-11
Growth drivers III-11
Current and Future Analysis III-12
A Regional Perspective III-12
Japan III-12
Prospects Weighed down by Regulatory Entanglements III-12
Japanese Coronary Stents Command Higher Prices III-12
Competitive Landscape III-12
China III-13
Healthcare Reforms to Propel Stent Market III-13
Strategic Corporate Development III-13
Kyoto Medical Planning Co., Ltd. - A Key Player III-13
B.Market Analytics III-14
Table 5: Asia-Pacific Current and Future Analysis for
Bioabsorbable Stents with Annual Sales in '000 Units for
Years 2013 through 2018 (includes corresponding Graph/Chart) III-14
4. REST OF WORLD III-15Market Analysis III-15Table 6: Rest of World Current and Future Analysis forBioabsorbable Stents with Annual Sales in '000 Units forYears 2013 through 2018 (includes corresponding Graph/Chart) III-15IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 16 (including Divisions/Subsidiaries - 17)
The United States (9)Japan (1)Europe (4)- France (1)- Germany (2)- The United Kingdom (1)Asia-Pacific (Excluding Japan) (3)
To order this report:: Global Bioabsorbable Stents Industry
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article